Autologous Bone Marrow Mononuclear Cells in Ischemic Cerebrovascular Accident Paves Way for Neurorestoration: A Case Report

Sharma, Alok; Sane, Hemangi; Nagrajan, Anjana; Gokulchandran, Nandini; Badhe, Prerna; Paranjape, Amruta; Biju, Hema

doi:10.1155/2014/530239

Cited by 11 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17-28 Despite testing in pre-clinical models and application in the clinical milieu, there are a number of unanswered questions regarding the use of BMMNCs in IS patients pertaining to dose, timing, route of administration and autologous vs. allogeneic approach. It is therefore important to study the pooled treatment effects of BMMNCs in relevant pre-clinical models of IS and explore sources of heterogeneity.…”

Section: Introductionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Vahidy¹,

Rahbar²,

Zhu³

et al. 2016

Stroke

View full text Add to dashboard Cite

Background and Purpose Bone marrow derived mononuclear cells (BMMNCs) offer the promise of augmenting post-stroke recovery. There is mounting evidence of safety and efficacy of BMMNCs from pre-clinical studies of ischemic stroke (IS), however their pooled effects have not been described. Methods Using PRIMSA guidelines, we conducted a systematic review of pre-clinical literature for intravenous use of BMMNCs followed by meta-analyses of histological and behavioral outcomes. Studies were selected based on pre-defined criteria. Data were abstracted by two independent investigators. Following quality assessment, the pooled effects were generated using mixed effect models. Impact of possible biases on estimated effect size was evaluated. Results Standardized mean difference (SMD), 95% confidence interval (CI) for reduction in lesion volume was significantly beneficial for BMMNC treatment (SMD −3.3, 95% CI: −4.3, −2.3), n = 113 each for BMMNC and controls. BMMNC treated animals (n = 161) also had improved function measured by cylinder test (SMD −2.4, 95% CI: −3.1, −1.6), as compared to controls (n = 205). A trend for benefit was observed for adhesive removal test and neurological deficit score. Study quality score (median: 6, Q1-Q3: 5-7) was correlated with year of publication. There was funnel plot asymmetry, however the pooled effects were robust to the correction of this bias and remained significant in favor of BMMNC treatment. Conclusions BMMNCs demonstrate beneficial effects across histological and behavioral outcomes in animal IS models. Though study quality has improved over time, considerable degree of heterogeneity calls for standardization in the conduct and reporting of experimentation.

show abstract

Section: Introductionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Vahidy¹,

Rahbar²,

Zhu³

et al. 2016

Stroke

View full text Add to dashboard Cite

show abstract

“…Mendonça et al found that intra-arterial autologous BMMNC transplantation was safe in acute ischemic stroke patients [80]. Autologous BMMNC therapies for stroke exhibited similar results in several later studies [81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99]. However, in a multicenter, randomized trial with blinded outcome assessment, Prasad et al found that autologous BMMNC therapy did not show beneficial effects in subacute ischemic stroke patients [100].…”

Section: Mononuclear Cellsmentioning

confidence: 99%

Clinical neurorestorative cell therapies: Developmental process, current state and future prospective

Huang

Chen

Mao

et al. 2020

Journal of Neurorestoratology

View full text Add to dashboard Cite

Clinical cell therapies (CTs) for neurological diseases and cellular damage have been explored for more than 2 decades. According to the United States Food and Drug Administration, there are 2 types of cell categories for therapy, namely stem cell-derived CT products and mature/functionally differentiated cell-derived CT products. However, regardless of the type of CT used, the majority of reports of clinical CTs from either small sample sizes based on single-center phase 1 or 2 unblinded trials or retrospective clinical studies showed effects on neurological improvement and the ability to either partially or temporarily thwart the deteriorating cellular processes of the neurodegenerative diseases. There have been only a few prospective, multicenter, randomized, double- blind placebo-control clinical trials of CTs so far in this developing novel area that have shown negative results, and more clinical trials are needed. This will expand our knowledge in exploring the type of cells that yield promising results and restore damaged neurological structure and functions of the central nervous system based on higher level evidence-based medical data. In this review, we briefly introduce the developmental process, current state, and future prospective for clinical neurorestorative CT.

show abstract

“…(2) Cell therapy is demonstrated by, a multicenter, randomized, double-blinded, and placebocontrolled clinical trial that OECs could effectively improve neurological dysfunction in patients with chronic stroke through olfactory sub-mucosa, which is suitable for mild, moderate, and severe neurological impairments. Other cells such as mononuclear cells [39][40][41][42][43][44]53], mesenchymal stromal cells [45][46][47][54][55][56], hematopoietic stem cells [57][58][59], mesenchymal stem cells [60,61], neural stem cells [49,62], and combination of different cells [63][64][65] are infused through intravenously, via the arteries or injected into subarachnoid space via lumbar puncture, or into the area surrounding the site of a stroke. All above have shown neurorestorative effects.…”

Section: Chronic Phasementioning

confidence: 99%

Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version)

Guo¹,

Xue

Zhao

et al. 2020

Journal of Neurorestoratology

View full text Add to dashboard Cite

Stroke is the main cause of death and disability among Chinese, and neurorestoration is an effective therapeutic strategy for patients with stroke. In recent years, many achievements have been made in stroke neurorestoration, but viewpoints for managing stroke vary per discipline. In order to promote standardization of diagnosis and treatment for stroke neurorestoration, the Chinese Association of Neurorestoratology (CANR; Preparatory) and China Committee of International Association of Neurorestoratology (IANR-China Committee) organized professional experts in the field to integrate fragmented neurorestorative methods and establish clinical diagnostic and therapeutic guidelines for stroke neurorestoration. This guideline includes the diagnosis and staging of stroke and therapeutic recommendations for neurorestoration at different stages of stroke in order to improve survival and quality of life of stroke patients.

show abstract

Autologous Bone Marrow Mononuclear Cells in Ischemic Cerebrovascular Accident Paves Way for Neurorestoration: A Case Report

Cited by 11 publications

References 13 publications

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Systematic Review and Meta-Analysis of Bone Marrow–Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Clinical neurorestorative cell therapies: Developmental process, current state and future prospective

Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version)

Contact Info

Product

Resources

About